| ￥3100 | |
| Z05954-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | |
| Protein Construction |
|
|
| Purity | > 95% as determined by Bis-Tris PAGE | |
| Endotoxin Level | Less than 0.05EU per μg by the LAL method. | |
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | |
| Expression System | HEK293 | |
| Theoretical Molecular Weight | 19.2 kDa | |
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 20-30 kDa based on Bis-Tris PAGE result. | |
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | |
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Serial dilutions of Anti-VEGF165 Antibody were added into VEGF165, Human, No Tag : Biotinylated Human VEGF R2, His Avi Tag binding reactioins. The half maximal inhibitiory concentration(IC50) is 0.30 μg/ml. »
Measured by a reporter gene assay using HEK293T-KDR-NFAT Cell line. The ED50 for this effect is < 10 ng/mL (QC Test). »
Immobilized VEGF165, Human, No Tag at 1 μg/ml(100 μI/well) on the plate. Dose response curve for Biotinylated Human VEGF R1, His Avi Tag with the EC50 of 42.7ng/ml determined by ELISA. »
Immobilized VEGF165, Human, No Tag at 1 μg/ml (100 μI/well) on the plate. Dose response curve for Anti-VEGF165 Antibody, hFc Tag with the EC50 of 3.1ng/ml determined by ELISA. »
Immobilized VEGF165, Human, No Tag at 5 μg/ml (100 μI/well) on the plate. Dose response curve for Human VEGF R2, His Tag with the EC50 of 1.56 μg/ml determined by ELISA. »
The purity of VEGF165, Human is greater than 95% as determined by SEC-HPLC. »
VEGF165, Human on Bis-Tris PAGE under reduced condition and Non reduced (N) condition. The purity is greater than 95%. »
| Target Background | Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis. |
| Synonyms | VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609;VEGF-165 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
